Peripheral Stent Implant Market

Peripheral Stent Implant Market Outlook (2024 to 2034)

The global peripheral stent implant market is calculated to reach a valuation of US$ 4.11 billion in 2024 and climb to US$ 7.76 billion by the end of 2034. This latest research study by skilled analysts at Fact.MR states that demand for peripheral stent implants is forecasted to rise at 6.6% CAGR from 2024 to 2034.

Peripheral artery disease (PAD) is a disorder where plaque builds up in the arteries supplying blood to the brain, kidney, intestines, and limbs as well as the belly, and it is treated with a peripheral stent. Stents are artificial tubular mesh constructions that are utilized to increase vessel potency in either native or grafted vasculature, whether they are peripheral, intravascular, or endovascular.

After implantation, a stent is intended to offer mechanical radial support. A balloon or self-expanding mechanism is used to expand the stent once it has been placed in the desired location. The market is exhibiting steady growth due increasing prevalence of peripheral artery disease (PAD) and the requirement for such treatment for the aging population.

Key Market Growth Drivers

• Growing demand for minimally invasive procedures and the increasing prevalence of peripheral artery disease are key factors contributing to the peripheral stent implant market growth. Minimally invasive procedures help improve the quality of life while lowering morbidity and mortality.
• There are more options for treating PAD due to recent advancements in radiation, gene therapy, imaging material and device technologies, and implementation. Drug-eluting technology, excisional atherectomy, and balloon angioplasty are examples of percutaneous intervention techniques.
• Because peripheral stents are less intrusive and more affordable and need a shorter recovery period than surgical revascularization, they are a favored choice for cases with acute recoil and stenosis.
• Key market players are focusing on the development of novel absorbable stents and peripheral local drug delivery such as antiproliferative and antithrombotic medication for the treatment and prevention of restenosis with less adverse effects or complications, such as thrombosis and bleeding.

Report Attribute	Detail
Peripheral Stent Implant Market Size (2024E)	US$ 4.11 Billion
Forecasted Market Value (2034F)	US$ 7.76 Billion
Global Market Growth Rate (2024 to 2034)	6.6% CAGR
North America Market Share (2024E)	51.7%
East Asia Market Value (2024E)	US$ 378 Million
Sales of Bare Metal Stents (2034F)	US$ 5.88 Billion
Sales of Fem-Pop Artery Stents (2034F)	US$ 2 Billion
Hospitals Segment Market Share (2034F)	US$ 4.38 Billion
Key Companies Profiled	Biotronik SE & Co. KG; W. L. Gore & Associates Inc.; Abbott Laboratories; Cook Medical, Inc.; B. Braun Melsungen AG; Medtronic Plc.; Terumo Medical; Microport Scientific Corporation; Boston Scientific Corporation; Terumo Corporation; iVascular SLU; Cardinal Health, Inc.

What are the Key Contributors to Growing Demand for Peripheral Stent Implants?

“Increasing Preference among Patients for Outpatient Treatments Due to Their Cost Effectiveness”

Expansion of the peripheral stent implant market size is driven by the growing preference for outpatient treatments over inpatient procedures due to several benefits such as shorter hospital stays, a decreased risk of hospital-acquired infections, and more affordable healthcare. The demand for outpatient operations is rising as more patients look for minimally invasive therapies that offer reduced chances of risks and a minimal period of recovery.

Patients desire outpatient operations, which are more convenient and accessible for them, contributing to market expansion. Also, because outpatient treatments enable more effective resource management, they lessen the strain on hospitals and healthcare providers.

Which Aspects are Restricting Sales Growth of Peripheral Stent Implants?

“High Cost of Manufacturing, Research, and Regulatory Compliance”

Development of new peripheral vascular devices typically requires advanced engineering, sophisticated materials, and high-end technology which leads to the high costs of manufacturing, research, and regulatory compliance. This is driving up the prices of devices. Healthcare organizations find it difficult to finance these devices due to the substantial expenditure required to purchase them, especially for small hospitals or clinics as they have budgets constrained. In the end, it makes it more difficult for them to give patients advanced medical care.

Peripheral stent implants come with various expenses that affect patients, healthcare providers, and institutions in addition to the devices' costs. These expenses cover the price of the anesthesia, surgical facilities, and operating room staff. The complexity of these procedures necessitates specialized equipment and an experienced medical team, which increases the overall costs.

Country-wise Insights

North America is poised to hold 51.7% of global peripheral stent implant market share in 2024. South Asia & Pacific is also estimated to hold a significant market share and is evaluated to provide ample growth opportunities in the coming years due to rising investments in healthcare infrastructure and the adoption of advanced medical technologies.

Why Do Suppliers See Lucrative Prospects in the United States?

“Well-Developed Healthcare Sector and Technological Advancements in Peripheral Stent Designs”

Attribute	United States
Market Value (2024E)	US$ 1.88 Billion
Growth Rate (2024 to 2034)	5.8% CAGR
Projected Value (2034F)	US$ 3.31 Billion

The field of peripheral artery disease (PAD) treatment is undergoing a revolution in the United States due to technological advancements in drug-eluting, material, and peripheral stent design. These initiatives are helping in enhancements of implants’ safety profiles, longevity, and effectiveness.

Introduction of bioresorbable scaffolds, for example, permits stents to progressively decompose within the body over time, potentially mitigating long-term difficulties linked to permanent implantation. The well-developed healthcare sector is a key factor that is supporting the market for peripheral stent implants in the United States, attracting patients from all over the world to get the best treatment.

• In May 2024, to treat chronic limb-threatening ischemia (CLTI) below the knee, the United States Food and Drug Administration authorized the Esprit BTK everolimus-eluting scaffold system. For the treatment of peripheral artery disease, it is the first drug-eluting resorbable scaffold to be licensed.

Which Peripheral Stent Implant Market Trends are Significant in China?

“Rising Funding for Healthcare Facilities and Availability of Advanced Treatments for PAD”

Attribute	China
Market Value (2024E)	US$ 206 Million
Growth Rate (2024 to 2034)	8.3% CAGR
Projected Value (2034F)	US$ 457 Million

China is projected to hold a leading position in 2024 with 54.6% market share in the East Asia region. The increasing funding for modern healthcare facilities and specialized treatment centers helps to improve the availability of advanced treatments for conditions such as peripheral artery disease (PAD). With these ongoing improvements in healthcare facilities, patients are now getting timely diagnoses, evaluations, and treatment, including the option of peripheral stent implants. These advancements are not only satisfying the needs of patients with vascular diseases but also contributing to revenue growth in the market in China.

Category-wise Insights

Based on artery type, the market is segmented into carotid artery stents, fem-pop artery stents, iliac artery stents, and infrapop artery stents. Demand for Iliac artery stents is increasing as they provide minimally invasive solutions for restoring blood flow in the iliac arteries, which are commonly affected by atherosclerosis and stenosis.

Which Peripheral Stent Implant Product is Widely Preferred?

“Low Risk and Long-term Benefits of Drug-Eluting Stents”

Attribute	Drug-Eluting Stents
Segment Value (2024E)	US$ 639.7 Million
Growth Rate (2024 to 2034)	6.9% CAGR
Projected Value (2034F)	US$ 1.25 Billion

Demand for drug-eluting stents (DESs) growing at high space compared to other product types because they outperform bare-metal stents in terms of long-term results and restenosis risk reduction. Drugs that prevent the formation of scar tissue are coated on DES, which lowers the risk that the artery will re-occur after the stent is inserted. Patients who have a high risk of restenosis and those with complicated lesions benefit most from this characteristic.

Technological advancements have also enhanced the delivery and design of DES, increasing its effectiveness and safety. Due to this, drug-eluting stents are becoming a preferred choice for doctors and patients, which is fueling the market for peripheral stent implants.

Why Do Hospitals Generate Significant Revenue for Peripheral Stent Implant Suppliers?

“Availability of Sophisticated Equipment and Wide Range of Interventional Treatments”

Attribute	Hospitals
Segment Value (2024E)	US$ 2.35 Billion
Growth Rate (2024 to 2034)	6.4% CAGR
Projected Value (2034F)	US$ 4.38 Billion

Hospitals are the main facilities where peripheral stent implantation treatments are performed. Hospitals offer a centralized setting and provide a wide range of interventional treatments, including peripheral stent implantation. Hospitals usually have sophisticated equipment, including advanced catheterization labs and skilled medical teams.

Established contacts with producers of medical devices make it easier for hospitals to obtain and use peripheral stent implants. Hospital-based services generally receive a sizable share of government healthcare spending due to reimbursement policies and healthcare financing schemes.

Competitive Landscape

Key players in the peripheral stent implant market are introducing advanced yet budget-friendly products to capture a significant market share by using several market strategies such as collaborations, mergers, and acquisitions.

• In March 2024, the first patient was enrolled in the "AGILITY" investigational device exemption (IDE) study, which aims to evaluate the safety and efficacy of the Becton, Dickinson and Company’s vascular-covered stent for the treatment of peripheral arterial disease (PAD).
• In October 2023, MedAlliance, a Swiss company that develops drug-eluting balloon technology, was acquired by Cordis, a global leader in the research and production of interventional cardiovascular and endovascular technologies.
• In August 2021, Royal Philips announced that it had reached an agreement on acquiring Vesper Medical Inc., a company located in the United States that provides minimally invasive peripheral vascular devices.
• In December 2020, the EFEMORAL I FIH clinical research was the first-in-human (FIH) use of Efemoral Medical's bioresorbable vascular scaffold system (EVSS) with FlexStep Technology. To relieve symptoms and prevent reintervention for this traditionally difficult patient group, the bioresorbable stent is intended to treat a wide variety of patients with peripheral artery disease (PAD).

Fact.MR provides detailed information about the price points of prominent manufacturers of peripheral stent implants positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Peripheral Stent Implant Market Research

• By Product :

  • Bare Metal Stents
  • Covered Stents
  • Drug-Eluting Stents

• By Artery :

  • Carotid Artery Stents
  • Fem-Pop Artery Stents
  • Iliac Artery Stents
  • Infrapop Artery Stents

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers/Outpatient

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa